Top in cardiology: Alirocumab ruling; trials target lipoprotein(a)
Click Here to Manage Email Alerts
A unanimous U.S. Supreme Court decision has allowed Regeneron and Sanofi to continue selling alirocumab after Amgen alleged they infringed two of its patents for PCSK9 inhibitor technology.
Ruling that Amgen’s patents were invalid, Justice Neil Gorsuch wrote that lower courts had “correctly concluded that Amgen failed ‘to enable any person skilled in the art ... to make and use the [invention]’ as defined by the relevant claims.” It was the top story in cardiology last week.
The second top story was the latest installment of the Pipeline Pulse column, which examined two phase 3 cardiovascular outcomes trials trying to reduce cardiovascular events through lipoprotein(a) reduction.
Read these and more top stories in cardiology below:
Supreme Court decision allows alirocumab to stay on US market
The U.S. Supreme Court unanimously ruled in favor of Regeneron and Sanofi that two of Amgen’s patents for PCSK9 inhibitor technology were invalid, allowing alirocumab to stay on the U.S. market. Read more.
Lipoprotein(a): The next frontier in cardiovascular risk reduction
This installment of Pipeline Pulse focuses on a single cardiovascular risk factor, lipoprotein(a), and examines two cardiovascular outcomes trials aimed at reducing cardiovascular events through Lp(a) reduction. Read more.
FDA approves sensor-enabled atrial fibrillation ablation catheter
Abbott announced the FDA approved its sensor-enabled ablation catheter for treatment of atrial fibrillation. Read more.
Hearts from donors with COVID-19 at time of death may confer worse survival for recipients
Transplant recipients with donor hearts from people who had active COVID-19 at time of death had worse 6-month and 1-year survival outcomes than those who had hearts from donors recovered from or without COVID-19, researchers reported. Read more.
‘Troubling numbers’ reveal pandemic’s toll on CV deaths, widening race disparities
In 2020, heart disease remained among the leading causes of death, even amid the COVID-19 pandemic, which may have exacerbated preexisting cardiovascular morbidity-related racial and ethnic disparities. Read more.